| Yang, Lin |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT04848753: Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 3 | 663 | RoW | Toripalimab combined with cisplatin and paclitaxel, Placebo combined with cisplatin and paclitaxel | Shanghai Junshi Bioscience Co., Ltd. | Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | 05/27 | 05/27 | | |
NCT06405139: Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 36 | RoW | Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine, Nanoliposomal Irinotecan, Oxaliplatin, Capecitabine | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Colorectal Cancer | 04/26 | 04/27 | | |
NCT06711471: Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer |
|
|
| Recruiting | 2 | 31 | RoW | trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab | LIN YANG | Gastric Cancer Adenocarcinoma Metastatic | 11/26 | 11/27 | | |
NCT06761846: Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ |
|
|
| Recruiting | 2 | 70 | RoW | Sintilimab plus Chemotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma | 06/26 | 12/27 | | |
NCT06750861: QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC |
|
|
| Not yet recruiting | 2 | 30 | RoW | QL1706 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Pancreatic Adenocarcinoma | 06/26 | 12/26 | | |
NCT05970302: XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC |
|
|
| Recruiting | 2 | 52 | RoW | Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Tislelizumab, Bevacizumab, Oxaliplatin, Capecitabine, MSS/pMMR, Metastatic Colorectal Cancer (mCRC), RAS-mutated, First-Line | 07/25 | 07/26 | | |
NCT04380103: A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer |
|
|
| Recruiting | 1/2 | 106 | RoW | XELOXIRI/Bevacizumab, Irinotecan, Oxaliplatin, Capecitabine, Bevacizumab | Chinese Academy of Medical Sciences | Metastatic Cancer, Colorectal Cancer, Colorectal Adenocarcinoma | 12/20 | 09/22 | | |
NCT05016869: Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer |
|
|
| Recruiting | 1/2 | 48 | RoW | fruquintinib plus capecitabine | Chinese Academy of Medical Sciences | Metastatic Colorectal Cancer | 02/23 | 08/24 | | |
NCT06034964: Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC |
|
|
| Active, not recruiting | N/A | 60 | RoW | Tislelizumab, BGB-A317 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Tislelizumab, Chemotherapy, First-line, Gastric Cancer Stage IV | 11/22 | 11/25 | | |
NCT05872581: Education Program of Hand Hygiene for Nursing Students |
|
|
| Completed | N/A | 280 | RoW | Hand scanner instant feedback, Video training | The Hong Kong Polytechnic University | Hand Hygiene | 07/23 | 07/23 | | |
| Active, not recruiting | N/A | 40 | Canada | Tai Chi Prehabilitation, Usual care | AHS Cancer Control Alberta, Canadian Cancer Society (CCS) | Prostate Cancer | 08/23 | 10/24 | | |
NCT06417892: Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma |
|
|
| Recruiting | N/A | 60 | RoW | PD-1inhibitor, PD-1 antibody, Fruquintinib, albumin paclitaxel, nab-paclitaxel | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Gastric Cancer | 05/26 | 12/26 | | |
NCT06211660: An Edge AI-based AR System for Hand Hygiene Training in Undergraduates of Health Related Disciplines |
|
|
| Recruiting | N/A | 240 | NA | AI-based AR training system, Hand scanner and Video training | The Hong Kong Polytechnic University | Hand Hygiene | 12/24 | 03/25 | | |
NCT04905537: Study on Early Genetic Screening and Precise Strategy of Neonatal Critical Illness |
|
|
| Recruiting | N/A | 4000 | RoW | No intervention | Children's Hospital of Fudan University, International Peace Maternity and Child Health Hospital, Obstetrics & Gynecology Hospital of Fudan University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Children's Medical Center, Shanghai Children's Hospital | Genetic Screening, Hereditary Disease, Newborn, Stillbirth | 11/24 | 12/24 | | |
| Not yet recruiting | N/A | 342 | RoW | Osimertinib, Alectinib, TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy | Guangdong Association of Clinical Trials, Nanjing Geneseeq Technology Inc. | Non-Small Cell Lung Cancer | 01/29 | 01/32 | | |
NCT04830826: A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China |
|
|
| Recruiting | N/A | 2000 | RoW | Surgeries | The First Affiliated Hospital of Guangzhou Medical University | NSCLC, Stage I, NSCLC, Stage II, NSCLC, Stage III | 01/24 | 07/24 | | |
| Wu, Jinquan |
NCT04381143: ASPIrin in Reducing Events in Dialysis ( ASPIRED ) |
|
|
| Recruiting | 4 | 9000 | RoW | Aspirin 100 mg Oral Tablet, Matching Placebo | Guangdong Provincial People's Hospital, The George Institute | CKD (Chronic Kidney Disease) Stage 5D | 09/26 | 12/26 | | |
